Special Issue "Cancer Smart Nanomedicine"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: 9 June 2023.

Special Issue Editors

Dr. Marina Pinheiro
E-Mail Website
Guest Editor
1. LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, 4050-313 Porto, Portugal
2. CHUP, Centro Hospitalar Universitário do Porto, 4050-313 Porto, Portugal
Interests: medicinal and pharmaceutical sciences; infectious and cancer diseases; nanomedicine and nanotechnology; drug development and drug delivery; drug-membrane interaction studies
Special Issues, Collections and Topics in MDPI journals
Dr. Ammad Ahmad Farooqi
E-Mail
Guest Editor
Institute of Biomedical and Genetic Engineering (IBGE), Islamabad 54000, Pakistan
Interests: Cancer, Cell Signaling; Apoptosis; Molecular Oncology; miRNA

Special Issue Information

Dear Colleagues,

Nanomedicine is revolutionizing the treatment of cancer. The use of nanoparticles has the potential to modulate cancer cells and contribute to the higher anticancer chemotherapy and immunotherapy efficacy. Nanomedicine can be exploited in biomedicine for applications, including imaging, drug delivery and targeting. This Special Issue, “Cancer Smart Nanomedicine”, published by the journal Cancers, seeks contributions assessing state-of-the-art research as well as future developments in the field of the prevention, diagnosis and treatment of cancer using nanomedicine. Topics include, but are not limited to, the use of nanoparticles as drug delivery systems for the prevention, diagnosis and treatment of different cancers, including liposomes, lipid nanoparticles, polymeric and gold nanoparticles, among others. Authors are invited to submit their latest results. Original papers and reviews are welcome.

Dr. Marina Pinheiro
Dr. Ammad Ahmad Farooqi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery
  • cancer
  • nanomedicine
  • nanoparticles
  • targeted-therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Smart Modification on Magnetic Nanoparticles Dramatically Enhances Their Therapeutic Properties
Cancers 2021, 13(16), 4095; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13164095 - 14 Aug 2021
Cited by 2 | Viewed by 910
Abstract
Magnetic nanoparticles (MNP) are employed as nanocarriers and in magnetic hyperthermia (MH) for the treatment of cancers. Herein, a smart drug delivery system composed of MNP functionalized with the cytotoxic drug gemcitabine (MNP-GEM) has been thoroughly evaluated. The linker employed is based on [...] Read more.
Magnetic nanoparticles (MNP) are employed as nanocarriers and in magnetic hyperthermia (MH) for the treatment of cancers. Herein, a smart drug delivery system composed of MNP functionalized with the cytotoxic drug gemcitabine (MNP-GEM) has been thoroughly evaluated. The linker employed is based on a disulfide bond and allows the controlled release of GEM under a highly reducing environment, which is frequently present in the cytoplasm of tumor cells. The stability, MH, and the interaction with plasma proteins of the nanoparticles are evaluated, highlighting their great potential for biological applications. Their cytotoxicity is assessed in three pancreatic cancer cell lines with different sensitivity to GEM, including the generation of reactive oxygen species (ROS), the effects on the cell cycle, and the mechanisms of cell death involved. Remarkably, the proposed nanocarrier is better internalized than unmodified nanoparticles, and it is particularly effective in PANC-1 cells, resistant to GEM, but not in non-tumoral keratinocytes. Additionally, its combination with MH produces a synergistic cytotoxic effect in all cancer cell lines tested. In conclusion, MNP-GEM presents a promising potential for treating pancreatic cancer, due to multiple parameters, such as reduced binding to plasma proteins, increased internalization, and synergistic activity when combined with MH. Full article
(This article belongs to the Special Issue Cancer Smart Nanomedicine)
Show Figures

Graphical abstract

Back to TopTop